Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that Scott Maguire, CEO of Xenetic Biosciences, will present at the LD Micro Main Event 2016 Annual Conference on Wednesday, December 7, 2016 at 4:30 p.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. During his presentation, Mr. Maguire will provide a corporate update and discuss the Company's clinical and regulatory progress for its in-house product candidates, as well as those being developed with Xenetic's partners. Xenetic's current in-house product pipeline includes Virexxa® (sodium cridanimod), which is being evaluated for the treatment of endometrial cancer and triple negative breast cancer, and ErepoXen™, a polysialylated form of erythropoietin (EPO), a hormone created by the kidneys to maintain red blood cell production and address anemia. Xenetic is also currently evaluating OncoHist™ for the treatment of acute myeloid leukemia (AML) in refractory patients. Mr. Maguire will also discuss the Company's up to $100 million license deal with Shire, one of the Company's largest shareholders, along with the clinical status of their product candidate. A live webcast of the presentation will be available by accessing the IR Calendar in the Investors section of Xenetic's website ( www.xeneticbio.com). A replay of the webcast will be available for 90 days, starting approximately two hours after the presentation ends. About Xenetic Biosciences Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs.